Partners News Investment in ARNE helps neonatologists make better decisions when treating newborn babies

28 April 2022

ARNE B.V. has raised financing from Oost NL and venture builder NLC. ARNE supplies smart software with which neonatologists can make decisions based on data after the birth of a child. This reduces the number of unintended mistakes and improves the survival of babies who are in critical condition shortly after birth. With the financing, ARNE can further develop the product and achieve the first commercial traction. Oost NL provides the investment from ION+, NLC from their Momentum fund.

In the Netherlands, one in ten babies receive breathing support just after birth and significant interventions are required in one percent of the cases. This is the 'Newborn Life Support' (NLS) protocol, an instructional overview on how to act in babies with complications after delivery. Because neonatologists, doctors who care for sick or premature babies, often must make important decisions in stressful and medically urgent situations, in 55 percent of the cases this NLS protocol is unintentionally deviated from. Additional training in this protocol is not sufficient, only 39 percent of doctors pass a re-exam.

For this reason, Tim Antonius, neonatologist at Radboud UMC and trainer of the NLS protocol, and his team developed smart software that helps doctors make decisions based on the available data. Based on certain vital parameters of the newborn baby, such as heart rate and oxygen saturation, an algorithm determines which steps the doctor can best take.

Touchscreen with vital information of vital importance

The NLS protocol is now available as a PDF document or paper version. A neonatologist logically does not have time to search such a document in critical situations. The funding will allow ARNE to continue developing the electronic decision support system (eDST), which presents essential information in an audiovisual manner. As a result, the doctor has his or her hands free and it is always clear what the next step in the NLS protocol is. The software can be used via a touchscreen that is installed on the car in the resuscitation room near the delivery room.

Reducing accidental errors

As part of the transaction, ARNE will establish itself in Ede. Rob de Vroet, CEO at ARNE: “We are very happy with the support from Oost NL and Momentum, because it allows us to take major steps in improving our product and bringing eDST to the market. We have been in contact with Oost NL for a long time. For example, in an earlier phase we met with the Business Angels Network, and we hired the necessary legal expertise with the help of a voucher provided via De Groeiversneller.”

Oost NL provides the investment from ION+. ION+ is an innovation fund for SMEs in Gelderland and is financed by the province of Gelderland and a contribution from the European subsidy program OP-Oost. “Every neonatologist deserves the best support to give newborn babies the best possible start. ARNE shows that smart software can make a difference in the follow-up of the NLS protocol, a textbook example of the strong development of medical technology in the Eastern Netherlands”, says Thomas Hensel, senior investment manager at Oost NL.

NLC has been involved with ARNE as a co-founder of the company since 2019, having previously provided initial funding through their Momentum fund during the venture's start-up phase. Together with Oost NL, NLC is now making new capital available through the Momentum fund to be able to introduce this technology to the market. “We are very excited about the developments that ARNE has gone through in recent times, and are therefore happy to continue to support Tim, Rob and the rest of the team in their mission to give all babies the right start,” says Lars Olthof , Venture Finance Expert at NLC.

*Find the original article here (in Dutch)

Related news items


Joining forces increases innovation Janssen and Radboud

1 December 2022

Dr. Eng Kinga MatuĊ‚a (KM), specialist in single-cell multi-omics and Jeroen Van Houdt (JH), Omics group leader at Janssen Pharmaceutica, answer three pressing questions about the successful collaboration in the single-cell technology project.

read more

Successful matchmaking at Radboudumc Investment Day  

7 October 2022

On the 5th of October, over 100 scientists, investors and entrepreneurs came together at the second Radboudumc Investment Day, jointly hosted by Radboudumc, Oost NL and Briskr.

read more

Radboudumc Investment Day 2022

26 September 2022

Get ready for Radboudumc Investment Day 2022: October 5 in Nijmegen!

read more

Thomas van den Heuvel wins Stairway to Impact Award for safer pregnancies using AI Award for safer pregnancies using AI

1 December 2021

Radboudumc researcher Thomas van den Heuvel receives the Stairway to Impact Award from Dutch Research Council NWO. He receives this prize for the development of the BabyChecker, a smartphone application that allows midwives to make ultrasounds during pregnancies.

read more

Department of Medical Imaging takes fourth spot in world hospital rankings

29 October 2021

US News rates the Department of Medical Imaging at Radboudumc with a fourth place in the international ranking of best global institutes for Radiology and Nuclear Medicine

read more

New start-up Patholyt will bring AI research into pathology diagnostics

21 September 2021 Patholyt is on a mission to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients worldwide. Patholyt is a spin-off from Radboudumc, a frontrunner in computational pathology research. read more